InvestorsObserver
Sign Up Login

CGEN Compugen Ltd

$0.69 $0.01 (0.83%)
Add to Watchlist Compare
Overall

CGEN Stock Analysis Overview

What this means: InvestorsObserver gives Compugen Ltd (CGEN) an overall rank of 39, which is below average. Compugen Ltd is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 39 means that 61% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

CGEN Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

CGEN Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

CGEN Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

CGEN Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

CGEN Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

CGEN Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

CGEN Stock Analysis Overview

What this means: InvestorsObserver gives Compugen Ltd (CGEN) an overall rank of 39, which is below average. Compugen Ltd is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 39 means that 61% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full CGEN report

CGEN Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

CGEN Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

CGEN Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

CGEN Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

CGEN Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

CGEN Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Compugen Ltd (CGEN) Analyst Forecast

CGEN Price, Volume, Earnings, and Dividend Date

  • Last Price $0.69
  • Previous Close $0.68
  • Change $0.01
  • Open $0.70
  • Volume 896,163
  • Avg. Volume (100-day) 1,049,728
  • Market Cap 59,771,004
  • Days Range 0.62 - 0.7098
  • 52-week Range 0.66 - 7.48
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E —
  • EPS —
  • Earnings Date 11/11/22
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta 1.254
  • PEG Ratio —

Compugen Ltd (CGEN) Company Description

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its innovative immuno-oncology pipeline consists of four clinical stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

Compugen Ltd (CGEN) Stock Chart

View Interactive CGEN chart

My Watchlists

Follow Your Favorite Stocks

Top Stocks in Biotechnology

Company Price
Logicbio Therapeutics Inc (LOGC) (LOGC) $2.03
Ardelyx Inc (ARDX) (ARDX) $1.51
Liquidia Corp (LQDA) (LQDA) $5.58
Axsome Thera (AXSM) (AXSM) $46.08
Satsuma Pharmaceuticals Inc (STSA) (STSA) $5.18
Minerva Neuroscie (NERV) (NERV) $10.15
G1 Therapeutics Inc (GTHX) (GTHX) $13.24
Wave Life Sci Ord Sh (WVE) (WVE) $3.66
Savara Inc (SVRA) (SVRA) $1.49
Capricor Therap (CAPR) (CAPR) $6.10